Targeted therapies, such as the ToGA trial (Trastuzumab for Gastric Cancer), was a pivotal phase III study that established the efficacy of adding trastuzumab to chemotherapy in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. This evidence concerns the gene ERBB2 and gastric cancer.